solanezumab
Sign in to saveSolanezumab (proposed INN, LY2062430) is a monoclonal antibody being investigated by Eli Lilly as a neuroprotector for patients with Alzheimer's disease. The drug originally attracted extensive media coverage proclaiming it a breakthrough, but it has failed to show promise in Phase III trials.
~6 min read
Encyclopedic overview
13 sectionsContents
- Medical uses
- Adverse effects
- Pharmacology
- Mechanism of action
- Manufacturing
- Society and culture
- Commercial aspects
- Preclinical trials
- Clinical trials
- Phase 1
- Phase 2
- Phase 3
- References
Solanezumab (proposed INN, LY2062430) is a monoclonal antibody being investigated by Eli Lilly as a neuroprotector for patients with Alzheimer's disease. The drug originally attracted extensive media coverage proclaiming it a breakthrough, but it has failed to show promise in Phase III trials.
== Medical uses == Solanezumab was safely used in combination with approved Alzheimer's disease treatment, such as acetylcholinesterase inhibitors or memantine, in the clinical trials.
Excerpted from Wikipedia’s “solanezumab” article, available under the CC BY-SA 4.0 licence.